Ⅱ类人白细胞抗原等位基因与晚期肝脾型日本血吸虫病的相关性研究

目的　探讨Ⅱ类人白细胞抗原 (HLA-Ⅱ)基因多态性与晚期肝脾型日本血吸虫病的相关性。　方法　用聚合酶链反应-序列特异性引物 (PCR-SSP)技术对 46例晚期肝脾型日本血吸虫病患者 (实验组 )和 43例慢性日本血吸虫病患者 (对照组 )HLA-DRB1、DPA1、DQA1和DQB14个基因位点的等位基因进行分型。对两组间等位基因频率的差异进行 χ² 检验。　结果　实验组HLA-DRB1*04、DPA1*0103、DQA1*0601和DQB1*020 1等位基因频率明显高于对照组 ,而HLA-DQA1*0501和DQB1*0601等位基因频率明显低于对照组。　结论　HLA-DRB1*04、DPA1*0103、DQA1*0601和DQB1*0201等位基因 ,因其与晚期肝脾型日本血吸虫病呈显著的正相关 (P <0.0 5 )而可能是该病的遗传易感基因 ,而HLA-DQA1*0501和DQB1*0601等位基因与对该病存在抵抗性有关。     

Graves病白细胞减少易感性与HLA-DRB1基因多态性的关联

目的探讨天津地区汉族Graves病(GD)白细胞减少易感性与HLA-DRB1基因多态性的关联.方法采用聚合酶链反应-序列特异性引物(PCR-SSP)方法检测45例GD白细胞减少患者、50例GD白细胞正常患者和90名正常对照的HLA-DRB1等位基因频率.结果(1)在不考虑白细胞变化的情况下,GD患者DRB1*08基因频率明显高于对照组(P＜0.01,RR=2.62),DRB1*07基因频率明显低于对照组(P＜0.01,RR=0.24).(2)GD白细胞减少组DRB1*08(P＜0.01,RR=4.17)和DRB1*15(P＜0.05,RR=1.69)基因频率较对照组显著增高,DRB1*07基因频率明显低于对照组(P＜0.01,RR=0.13).(3)GD白细胞减少组DRB1*08基因频率(P＜0.01)和DRB1*15基因频率(P＜0.05)均明显高于白细胞正常组,DRB1*09(P＜0.05)基因频率明显低于白细胞正常组.结论天津地区汉族GD白细胞减少易感性与HLA-DRB1*08,HLA-DRB1*15基因频率增加有关;GD的保护性与HLA-DRB1*07基因频率减少有关.     

人类白细胞抗原DRB1基因与肺结核的相关性研究

目的探讨HLA-DRB1基因多态性与肺结核(PTB)的遗传关联性及其与临床表现的关系。方法采用聚合酶链反应-序列特异性引物(PCR-SSP)方法,对74例PTB患者及90名正常人的HLA-DRB1等位基因进行分型。结果与对照组相比,PTB病例组的DRB1*15等位基因频率显著增高(34.3%比17.0%,Pc<0.05,RR=2.91),HLA-DRB1*12基因频率高(15.4%比7.5%),但统计学上无显著性差异(Pc>0.05);而DRB1*11基因频率显著低于对照组(1.4%比9.9%,Pc<0.05,RR=0.12)。HLA-DRB1*15阳性患者中复治病例数和耐药病例数均显著高于HLA-DRB1*15阴性组(P<0.05)。结论HLA-DRB1*15可能是PTB的易感基因,DRB1*11可能为保护基因,HLA-DRB1*15基因与PTB临床特征有一定相关性。     

抗甲状腺药物致白细胞减少易感性与HLA-DRB1基因多态性及ANCA的关联性

目的 研究安徽地区汉族Graves病患者使用抗甲状腺药物(ATD)致白细胞减少的易感性与HLA-DRB1基因多态性及抗中性粒细胞胞浆抗体(ANCA)的相关性.方法 采用聚合酶链反应-序列特异性引物方法(PCR-SSP)检测76例ATD致白细胞减少的Graves病患者、98例ATD治疗后白细胞正常患者和230名健康对照者的等位基因HLA-DRB1* 08032、DRBI* 1501、DRB1*0901的频率.采用间接免疫荧光法(IIF)检测白细胞减少组和白细胞正常组Graves病患者的血清ANCA阳性率.结果 (1)与健康对照组及细胞正常组比较,白细胞减少组患者等位基因DRB1 * 08032、DRB1*1501频率明显增加(OR分别为3.06,1.77,4.03和2.28,均P＜0.05),DRB1* 0901频率明显减低(OR为0.33和0.43,P＜0.05).(2)与甲巯咪唑治疗后白细胞正常组患者比较,甲巯咪唑致白细胞减少组患者血清ANCA阳性率明显增加(x2 =4.878,P＜0.05).(3)与未携带等位基因DRB1*08032和DRB1*1501的患者比较,携带者血清中ANCA阳性率明显增加(x2为5.682,5.429,4.009和4.549,均P＜0.05).结论 等位基因HLA-DRB1*08032、HLA-DRB1*1501可能是安徽地区汉族人ATD致白细胞减少的易感基因;HLA-DRB1*0901可能是其保护基因或抗性基因.免疫反应可能参与了ATD致白细胞减少的发生.免疫反应的发生可能存在遗传易感性.     

肺结核病患者与HLA-DRB1等位基因的关联

目的:通过对湖北省汉族肺结核病(PTB)患者进行HLA-DRB1基因分型,探讨此人群与HLADRB1的相关性。方法:用序列特异性寡核苷酸探针聚合酶链反应(PCR-SSOP)技术对174例PTB患者及1 358例健康人群进行HLA-DRB1基因分型。基因频率与Hardy-Weinberg平衡卡方检测使用arlequin软件进行,组间比较用Fisher精确概率法计算P值,检测水准为a=0.05,相对危险系数用RR表示,RR=A(A+B)/C(C+D)。结果:174例PTB患者HLA-DRB1基因分型结果与希望值进行H-W平衡检测(P0.05)。此人群检出HLA-DRB1等位基因共13种与对照组一致。其中RB1*08与DRB1*09基因频率显著高于对照组,差异有统计学意义(P0.01),且RR1,说明DRB1*08与DRB1*09或与其连锁的单倍型可能是的PTB易感基因;RB1*10与DRB1*13基因频率显著低于对照组,差异有统计学意义(P0.05),且RR1,说明RB1*10与DRB1*13可能是PTB的保护基因。其余等位基因频率组间比较均无统计学意义。结论:湖北省汉族PTB患者这个疾病群体遗传平衡被杂化,其与HLA-DRB1有一定的关联,但有其自身的特点。     

GD药物引起粒细胞减少与等位基因的关系

采用多聚酶链式反应-序列特异引物(pcr-ssp)方法检测65例GD病人抗甲状腺药物引起粒细胞减少(1)组,65例GD病人并发粒细胞减少(2)组,65例非GD病人粒细胞减少(3)组,65例正常参照人群(4)组的HLA-DRB1*08032 DRB1*1501的等位基因频率.结果 1(1)组HLA-DRB1*08032 DRB1*1501的基因频率高于(2)组(P＜0.05).2(1)组HLA-DRB1*08032 DRB1*1501的基因频率明显高于(3)组(4)组,(P＜0.01).3(2)组HLA-DRB1*08032DRB1*1501的基因频率高于(4)组(P＜0.05).结论GD病人应用抗甲状腺药物引起粒细胞减少与HLA-DRB1*08032DRB1*1501等位基因频率增加有关.     

HLA-DRB1和肿瘤坏死因子α基因多态性与肝硬化的遗传易感性

目的探讨HLA-DRB1和肿瘤坏死因子(TNF)α基因多态性与肝硬化遗传易感性之间的关系.方法应用聚合酶链反应-序列特异性引物法、限制性片段长度多态性等技术检测106例乙型肝炎后肝硬化患者和108例健康对照者的HLA-DRB1和TNFα基因多态性.结果肝硬化组HLA-DRB1*120X等位基因频率比对照组显著升高(35.9%比11.1%,P＜0.001),TNFα中TNF2/1基因型频率比对照组明显升高(19.8%比10.2%, P＜0.05),DRB1*150X等位基因频率明显低于对照组 (13.2%比30.6% ,P＜0.05),分层分析表明,DRB1*120X等位基因与肝硬化的关联大于TNF2等位基因.结论 HLA-DRB1*120X和TNF2等位基因与乙型肝炎后肝硬化的遗传易感性相关,携带这2个等位基因的个体发生肝硬化的危险性增加.HLA-DRB1*120X等位基因可能是肝硬化的易感基因,HLA-DRB1*150X等位基因为抗性基因.     

山东地区汉族骨髓捐献者HLA-DRB1基因分型及多态性分析

目的观察山东地区汉族人群人白细胞抗原(HLA)-DRB1基因多态性及其分布特点。方法采用聚合酶链反应—测序为基础的分型方法(PCR-SBT)对随机抽取的909例中华骨髓库山东分库内山东汉族骨髓供者血样进行HLA-DRB1基因分型和多态性分析。结果共检测出42种HLA-DRB1等位基因,其中HLA-DRB1*0901等位基因频率最高(16.28%),其次为HLA-DRB1*1501(15.13%)和HLA-DRB1*0701(14.04%),基因频率最低的是DRB1*0408、DRB1*0809、DRB1*1103、DRB1*1303、DRB1*1412、DRB1*1425、DRB1*1601,各占0.06%。山东汉族骨髓供者HLA-DRB1等位基因的分布与江苏、湖北、新疆、广东、韩国、日本和德国人群存在明显差异(P均<0.05)。结论掌握了山东地区汉族人群HLA-DRB1基因多态性及其分布特征。     

HLA-DRB1基因多态性与扩张型心肌病的相关分析

目的探讨扩张型心肌病（IDC）与人类白细胞抗原（HLA）-DRB1基因多态性的关系。方法用聚合酶链反应一序列特异性引物方法检测301例IDC患者（IDC组）与436例正常人（对照组）的HLA-DRB1等位基因分布情况。结果IDC组HLA-DRB1＊11、HLA-DRB1＊12、HLA-DRB1＊14的基因频率明显高于对照组（RR=2．91、4．02、3．78，P〈0．05）；IDC组同时携带HLA-DRB1＊12、DRB1＊14基因型的阳性率亦显著高于对照组（RR=6．24．P〈0．01）。结论HIA-DRB1＊11、DRB1＊12、DRB1＊14与IDC有明显相关性。     

肺结核病患者与HLA-DRBI等位基因的关联

目的：通过对湖北省汉族肺结核病（PTB）患者进行HLA-DRB1基因分型,探讨此人群与HLA-DRB1的相关性。方法：用序列特异性寡核苷酸探针聚合酶链反应（PCR-SSOP）技术对174例PTB患者及1358例健康人群进行HLA-DRB1基因分型。基因频率与Hardy-Weinberg平衡卡方检测使用arlequin软件进行,组间比较用Fisher精确概率法计算P值,检测水准为a=0．05,相对危险系数用RR表示,RR：A（A＋B）／C（C＋D）。结果：174例PTB患者HLA-DRB1基因分型结果与希望值进行H-W平衡检测（P〉0．05）。此人群检出HLA-DRB1等位基因共13种与对照组一致。其中RB1＊08与DRB1＊09基因频率显著高于对照组,差异有统计学意义（P〈O．01）,且RR〉1,说明DRB1＊08与DRB1＊09或与其连锁的单倍型可能是的PTB易感基因;RB1＊10与DRB1＊13基因频率显著低于对照组,差异有统计学意义（P〈0．05）,且RR〈1,说明RB1＊10与DRB1＊13可能是PTB的保护基因。其余等位基因频率组间比较均无统计学意义。结论：湖北省汉族PTB患者这个疾病群体遗传平衡被杂化,其与HLA-DRBl有一定的关联,但有其自身的特点。     

Association of the HLA-DRB1 gene with susceptibility to aortoarteritis in a Chinese Han population.

Aortoarteritis is a chronic inflammatory disease mainly affecting the aorta and its major branches. Recent immunogenetic studies indicate that certain human leucocyte antigen (HLA) alleles are significantly associated with aortoarteritis in several populations. The purpose of the present study was to investigate the relationship between the HLA-DRB1 alleles and aortoarteritis in a Chinese Han population. HLA-DRB1 genotypes were identified by PCR-SSP and PCR-RFLP in 84 Chinese patients with aortoarteritis and 102 healthy Chinese controls. It was found that the HLA-DRB1*04 allele (38.1% in patients vs. 15.7% in controls, p<0.001, relative risk (RR)=2.43) and the HLA-DRB1*07 allele (47.6% vs. 10.8%, p<0.001, RR = 4.42) were significantly associated with aortoarteritis. Furthermore, there was no significant difference in the frequency of the DRB1*0405 subtype between the patient and control groups. Thus the susceptibility to aortoarteritis in this Chinese Han population was closely related with the HLA-DRB1*04 and DRB1*07 alleles. Thus individuals with the HLA-DRB1*04 and DRB1*07 alleles may be at higher risk for developing aortoarteritis.     

Tnfluence of HLA-DRB1 alleles and HBV genotypes on interferon-α therapy for chronic hepatitis B

AIM: To investigate the influence of HLA-DRB1 alleles and HBV genotypes on interferon-α therapy for chronic hepatitis B.METHODS: HLA-DRB1*03, *07, *09, *12, *15 alleles were determined using polymerase chain reaction/sequence specific primer (PCR/SSP) technique in 126 patients with chronic hepatitis B and 76 normal control subjects in Shandong Province, and HBV genotypes were determined by nested-PCR analysis using type-specific primers in 126 patients.RESULTS: The positivity of HLA-DRB1*07 allele in chronic hepatitis B group was significantly higher than that in normal control group (x2 = 6.33, P<0.025, RR = 2.37). Among the 126 patients, genotype B was found in 38 (30.2%), genotype C in 69 (54.8%), and mixed genotype (B+C) in 19 (15.0%),genotypes D-F were not found. Among the 46 DRB1*07(+)patients, 7 were responders and 39 were non-responders among them (x2 = 6.71, P<0.05). The positivity of HLADRB1*07 and prevalence of HBV genotype C were significantly higher in non-responders than in responders.CONCLUSION: High positivities of HLA-DRB1 *07 allele and HBV genotype C are closely associated with the lower response to interferon-α therapy for chronic hepatitis B.     

Tnfluence of HLA-DRB1 alleles and HBV genotypes on interferon-α therapy for chronic hepatitis B

AIM: To investigate the influence of HLA-DRB1 alleles and HBV genotypes on interferon-α therapy for chronic hepatitis B.METHODS: HLA-DRB1*03, *07, *09, *12, *15 alleles were determined using polymerase chain reaction/sequence specific primer (PCR/SSP) technique in 126 patients with chronic hepatitis B and 76 normal control subjects in Shandong Province, and HBV genotypes were determined by nested-PCR analysis using type-specific primers in 126 patients.RESULTS: The positivity of HLA-DRB1*07 allele in chronic hepatitis B group was significantly higher than that in normal control group (x2 = 6.33, P<0.025, RR = 2.37). Among the 126 patients, genotype B was found in 38 (30.2%), genotype C in 69 (54.8%), and mixed genotype (B+C) in 19 (15.0%),genotypes D-F were not found. Among the 46 DRB1*07(+)patients, 7 were responders and 39 were non-responders among them (x2 = 6.71, P<0.05). The positivity of HLADRB1*07 and prevalence of HBV genotype C were significantly higher in non-responders than in responders.CONCLUSION: High positivities of HLA-DRB1 *07 allele and HBV genotype C are closely associated with the lower response to interferon-α therapy for chronic hepatitis B.     

HLA-DRB3*0101 is associated with Graves' disease in Jamaicans

OBJECTIVES: Graves' disease is associated with different human leucocyte antigen (HLA) genes in different populations. This studywasdesigned to examinethe HLA class II associations with Graves' disease in Jamaicans. PATIENTS: One hundred and six Jamaicans with Graves' disease and 104 controls. DESIGN: Oligotyping for HLA-DRB1, DRB3, DQA1 and DQB1 alleles was performed using the polymerase chain reaction sequence specific oligonucleotide probe (PCR-SSOP) technique. RESULTS The frequency of HLA-DRB3 *0101 was increased significantly in the patients compared to controls (38.7% vs. 19.2%; RR = 2.72; Pc < 0.015). The protective alleles for Graves' disease were DRB1 *0901 (0.9% vs. 20.2%; RR = 0.04; Pc < 0.001), DRB1*1001 (0.0% vs. 11%; RR = 0.0%; Pc < 0.01) and DRB4 *0101 (0.0% vs. 12.5%; RR = 0.0; Pc < 0.05). A high female to male ratio of Graves' disease, 25 :1, was observed. Other associated autoimmune diseases were rare and no significant HLA class II associations were found with clinical markers of disease. CONCLUSIONS: Jamaican patients with Graves' disease share the DRB3 *0101 susceptible allele and the DRB4 *01 protective allele but not the susceptible haplotype DRB1 *0301, DRB3*0101, DQA1*0501 with Caucasians.     

HLA haplotype analysis in Finnish patients with rheumatoid arthritis

OBJECTIVE: To further characterize the HLA gene products that play an important role in the pathogenesis of rheumatoid arthritis (RA). METHODS: One hundred thirty-four haplotypes from 67 Finnish RA patients and 77 control haplotypes were analyzed for HLA-DRB1 loci, associated alleles of the HLA-DQB1 locus, alleles of the type 2 transporter-associated antigen processing (TAP2) genes, and HLA-B27. In addition, a panel of microsatellite markers within the HLA class I and class III regions was studied. RESULTS: The frequency of HLA-DRB1*04 in the haplotypes of RA patients was found to be 34% (45 of 134) compared with 14% (10 of 72) in control haplotypes (P = 0.004). The frequency of HLA-DRB1*13 was decreased in RA haplotypes (4%, or 5 of 134) in contrast to control haplotypes (24%, or 17 of 72) (P = 0.000031). The decrease in DRB1*13 was not secondary to the increase in DRB1*04, since it was also found among DRB1*04-negative haplotypes (P < 0.001). The DRB1*13-associated DQB1*0604 allele was similarly decreased in RA haplotypes (P = 0.025). The TAP2I allele of I/J dimorphism was increased in RA patients (85%, or 114 of 134) as compared with controls (69%, or 49 of 71) (P = 0.011). Of the tumor necrosis factor (TNF) microsatellite alleles, TNFa6 and TNFb5 were found to be increased in RA haplotypes (for a6 27% versus 5% in controls [P = 0.00043], and for b5 43% versus 26% in controls [P = 0.037]). CONCLUSION: Both protection-associated and susceptibility-associated alleles can be found among HLA class II genes, and the results suggest that loci outside DR/DQ may contribute to the pathogenesis of RA.     

Analysis of single-nucleotide polymorphisms in Japanese rheumatoid arthritis patients shows additional susceptibility markers besides the classic shared epitope susceptibility sequences

OBJECTIVE: To examine the entire HLA region for loci (other than the DRB1 locus) associated with rheumatoid arthritis (RA) susceptibility, by typing HLA-DRB1 alleles and multiple single-nucleotide polymorphisms (SNPs) in the Japanese population. METHODS: The HLA-DRB1 alleles and 88 SNPs distributed over the HLA gene complex were genotyped, for 828 patients with RA and 1,032 control subjects. The data were evaluated for linkage disequilibrium, and case-control associations were analyzed in 2 ways, in the presence or absence of the disease-susceptibility DRB1 allele, to detect loci independent of the DRB1 allele. RESULTS: HLA-DRB1 alleles *0405, *0401, *0901, *0101, *1401, *1602, *0403, and *1405 were significantly associated with RA in the Japanese population. The smallest P value (P = 1.4 x 10(-27)) was observed in association with an intronic SNP of the NOTCH4 gene, which was due to strong linkage disequilibrium with the HLA-DRB1 allele. A strong association that was independent of HLA-DRB1 shared epitope alleles was observed in 2 SNPs: one in the intron of the MICA gene, the other in the intron of the HLA-DQB2 gene. Their association with RA, independent of HLA-DRB1 shared epitope alleles, was suggestive (P = 0.0024 [corrected P (P(corr)) = 0.068, and P = 0.00037 [P(corr) = 0.012], respectively). CONCLUSION: These findings suggest that 1 or more other loci besides the HLA-DRB1 or other DRB1 (non-shared epitope, non-*0901) alleles are involved in RA susceptibility/protection.     

Association between HLA-DR B1 and clinical features of adult onset Still's disease in Korea

OBJECTIVE: To determine whether HLA-DR alleles are associated with the development and clinical features of Adult Onset Still's Disease (AOSD) in Korea. METHODS: Forty-seven patients (41 women, 6 men, mean age at diagnosis 31.6 yr) meeting Yamaguchi's criteria for AOSD and 144 healthy controls were enrolled in this study. The patients with AOSD were subdivided into groups according to their chronicity: monocyclic systemic, polycyclic systemic, and chronic destructive type, and were furthermore classified as non-articular, oligoarticular or polyarticular types (having arthritis involving 5 or more joints) according to the extent of articular involvement. HLA-DRB1 genotypes were assessed by PCR-SSOP. RESULTS: Patients with AOSD had more frequent DRB1*12 (p = 0.028, relative risk (RR) = 2.27, 95% confidence interval (CI): 1.08-4.80) and DRB1*15 (p = 0.013, RR = 2.16, 95% CI: 1.17-4.00). They had less frequent DRB1*04 (p = 0.006, RR = 0.35, 95% CI: 0.16-0.75) compared to controls. DRB1*14 (p = 0.011, RR = 3.80, 95% CI: 1.27-11.31) were associated with the monocyclic systemic type. CONCLUSION: Korean AOSD patients had more frequent DRB1*12 and DRB1*15, and less frequent HLA-DRB1*04. The patients with the monocyclic systemic type had more frequent DRB1*14 alleles. This study suggests that Korean AOSD patients have distinct immunogenetic profiles, and that it would be valuable to assess the relationships between HLA-DRB1 genes and polymorphisms of proinflammatory cytokines in the pathogenesis of AOSD.     

lnfluence of HLA-DRB1 alleles and HBV genotypes on interferon-α therapy for chronic hepatitis B

AIM: To investigate the influence of HLA-DRB(1) alleles and HBV genotypes on interferon-alpha therapy for chronic hepatitis B. METHODS: HLA-DRB1*03, *07, *09, *12, *15 alleles were determined using polymerase chain reaction/sequence specific primer (PCR/SSP) technique in 126 patients with chronic hepatitis B and 76 normal control subjects in Shandong Province, and HBV genotypes were determined by nested-PCR analysis using type-specific primers in 126 patients. RESULTS: The positivity of HLA-DRB1*07 allele in chronic hepatitis B group was significantly higher than that in normal control group (chi(2) = 6.33, P<0.025, RR = 2.37). Among the 126 patients, genotype B was found in 38 (30.2%), genotype C in 69 (54.8%), and mixed genotype (B+C) in 19 (15.0%), genotypes D-F were not found. Among the 46 DRB1*07(+) patients, 7 were responders and 39 were non-responders among them (chi(2) = 6.71, P<0.05). The positivity of HLA-DRB1*07 and prevalence of HBV genotype C were significantly higher in non-responders than in responders. CONCLUSION: High positivities of HLA-DRB1 *07 allele and HBV genotype C are closely associated with the lower response to interferon-alpha therapy for chronic hepatitis B.     

The role of human leukocyte antigens as predisposing and/or protective factors in patients with idiopathic thrombotic thrombocytopenic purpura

Fifty-four adult German patients suffering from idiopathic thrombotic thrombocytopenic purpura (TTP) have been examined for HLA class II. All patients presented autoantibodies against ADAMTS13 and ADAMTS13 activity levels <5%. Blood samples have been analyzed for HLA-DRB1 and DQB1 alleles using sequence-specific primer PCR and sequence-specific oligonucleotide PCR. Reference data of German bone marrow and blood donors were obtained from . The results were evaluated employing two-sided binomial tests, and p values were corrected using the Benjamini–Hochberg procedure. A significant accumulation for DQB1*02:02 (p < 0.001) and DRB1*11 (p = 0.003) was found within the patient group. Twenty percent (DQB1*02:02) or 48.1% (DRB1*11) of TTP patients were tested positive for the particular HLA antigen compared to 1.2% (DQB1*02:02) or 23.5% (DRB1*11) in the control group. A tendency for a reduced occurrence of HLA-DRB1*04 was revealed (7.4% in patients compared to 24.6% in controls). An association between the HLA antigens DQB1*02:02 and DRB1*11 and disease susceptibility for idiopathic TTP has been found. A higher risk for disease outbreak within persons carrying the mentioned alleles can be assumed. The reduced occurrence of HLA-DRB1*04 in TTP patients indicates a possible protective effect of this HLA allele in disease development.